Pfizer Inc.
PFE
$25.88
$0.140.54%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 06/29/2025 | 03/30/2025 | 12/31/2024 | 09/29/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.65B | 13.72B | 17.76B | 17.70B | 13.28B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.65B | 13.72B | 17.76B | 17.70B | 13.28B |
| Cost of Revenue | 3.50B | 2.59B | 5.74B | 4.87B | 2.77B |
| Gross Profit | 11.15B | 11.12B | 12.02B | 12.83B | 10.52B |
| SG&A Expenses | 3.29B | 2.91B | 4.74B | 3.12B | 3.56B |
| Depreciation & Amortization | 1.21B | 1.21B | 1.36B | 1.31B | 1.31B |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.45B | 8.89B | 14.94B | 11.86B | 10.31B |
| Operating Income | 4.20B | 4.82B | 2.83B | 5.84B | 2.97B |
| Income Before Tax | 3.04B | 2.78B | -10.00M | 4.72B | -103.00M |
| Income Tax Expenses | 141.00M | -189.00M | -421.00M | 234.00M | -134.00M |
| Earnings from Continuing Operations | 2.90B | 2.97B | 411.00M | 4.48B | 31.00M |
| Earnings from Discontinued Operations | 25.00M | -- | 7.00M | -8.00M | 17.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -18.00M | -6.00M | -8.00M | -8.00M | -7.00M |
| Net Income | 2.91B | 2.97B | 410.00M | 4.47B | 41.00M |
| EBIT | 4.20B | 4.82B | 2.83B | 5.84B | 2.97B |
| EBITDA | 5.83B | 6.44B | 4.61B | 7.58B | 4.70B |
| EPS Basic | 0.51 | 0.52 | 0.07 | 0.79 | 0.01 |
| Normalized Basic EPS | 0.42 | 0.49 | 0.26 | 0.56 | 0.28 |
| EPS Diluted | 0.51 | 0.52 | 0.07 | 0.79 | 0.01 |
| Normalized Diluted EPS | 0.42 | 0.49 | 0.26 | 0.56 | 0.28 |
| Average Basic Shares Outstanding | 5.69B | 5.68B | 5.67B | 5.67B | 5.67B |
| Average Diluted Shares Outstanding | 5.71B | 5.71B | 5.70B | 5.71B | 5.70B |
| Dividend Per Share | 0.43 | 0.43 | 0.42 | 0.42 | 0.42 |
| Payout Ratio | -- | 82.14% | 580.49% | 53.30% | 5,804.88% |